AlphaMark Advisors »

Halozyme Therapeutics shares owned by AlphaMark Advisors

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by AlphaMark Advisors from 13F filings

Historical chart of AlphaMark Advisors investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by AlphaMark Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by AlphaMark Advisors

Quarter filed Position value Share count Share price at filing
2024-09-30 $325k 5.7k 57.27

More positions owned by AlphaMark Advisors

AlphaMark Actively Man Etf (SMCP)
iShares S&P 500 Index (IVV)
Health Care SPDR (XLV)
Technology SPDR Etf (XLK)
SPDR Trust Unit SR Etf (SPY)
Procter & Gamble Company (PG)
Sch Fnd Em Lg Etf schb fdt emk lg (FNDE)
Db-x Msci Eafe Currency-hedged (DBEF)
First Tr Exchng Traded Fd Vi tcw opportunis (FIXD)
Financial Select Sector SPDR (XLF)
Industrial SPDR (XLI)
Janus Detroit Str Tr (JAAA)
Select Sector Spdr Tr Communic etfeqty (XLC)
Energy Select Sector SPDR (XLE)
Consumer Staples Select Sect. SPDR (XLP)

View all positions for AlphaMark Advisors

Top funds holding Halozyme Therapeutics

BlackRock
BlackRock
Vanguard Group
State Street Corporation
Snyder Capital Management
Alliancebernstein
Artisan Partners Limited Partnership
Macquarie Group
Geode Capital Management
Jpmorgan Chase & Co
Congress Asset Management
Bank of America Corporation
Arrowpoint Asset Management
Handelsbanken Fonder AB
Invesco

View all funds holding Halozyme Therapeutics